mind & bodyanalysisSAPIENS
Gene Therapy’s Promise Meets Nigeria’s Sickle Cell Reality
Sickle cell anemia arose in Africa thousands of years ago and persisted because the trait protected against malaria. People with one normal and one sickle gene have roughly a tenfold lower malaria risk, since sickle hemoglobin carries less oxygen, which impairs parasite growth in red blood cells. Two copies of the sickle gene cause the disease itself, with fatigue, pain crises and organ damage. Newer gene therapies can now treat it, but they cost around $2 million per patient, far beyond most families in Nigeria.
Hemoglobin is the protein that carries oxygen in red blood cells. A single altered gene changes its shape so cells sickle under low oxygen, making them rigid and short-lived. Carrying one altered copy gives partial protection against malaria parasites, which struggle to grow in those cells.
The gap between a cure existing and people being able to get it is the central problem of sickle cell disease. Stigma, underdiagnosis and cost shape daily life for millions of people, especially in Africa where the disease is most common.
